Integrated DNA Technologies Launches New Enhancer Protein to Accelerate CRISPR-Based Therapies from Translational Research to Clinical Breakthrough

Research grade recombinant protein expands toolkit of available CRISPR nucleases and increases efficiency of homology-directed repair (HDR) to enable more precise genome modifications

CORALVILLE, Iowa--(BUSINESS WIRE)--Global genomics leader Integrated DNA Technologies (IDT) is driving innovation and leadership in CRISPR with the launch of Alt-R™ HDR Enhancer Protein, a newly developed solution designed to facilitate an up to two-fold increase in HDR efficiency in challenging cells, including iPSCs and HSPCs. This new, proprietary molecule expands IDT’s market-leading portfolio of HDR reagents to empower cell and gene therapy developers with an accelerated path for their therapeutic research programs. Manufactured by Aldevron, a leading global CDMO and fellow operating company of Danaher, to meet rigorous quality standards, Alt-R HDR Enhancer Protein maintains cell viability and genomic integrity, with no increase in off-target edits or translocations.

“IDT’s legacy of innovation, market leadership in CRISPR and strong collaborations with gene editing pioneers enabled us to develop a first-to-market Alt-R HDR Enhancer Protein that delivers on our customers therapeutic research needs and desire to fast-track breakthroughs,” said Sandy Ottensmann, VP/GM, Gene Writing & Editing at IDT. “It’s exciting to see from early access users that this pathway specific protein-based enhancer shifts the DNA repair pathway balance toward HDR, promoting more precise genome modification without compromising cell viability or genomic integrity, demonstrating its scalability in therapeutic development applications.”

While CRISPR-Cas systems are highly efficient at generating knockouts through NHEJ, knock-in via HDR remains a challenge in primary and difficult-to-edit cells. Various studies performed using IDT’s Alt-R HDR Enhancer Protein indicate a significant boost in HDR efficiency across multiple loci and cell types, highlighting the effectiveness of the novel, protein-based solution for basic research and translational applications. The findings also revealed that the Alt-R HDR Enhancer Protein preserves editing specificity and is well-suited for high-fidelity editing workflows, providing researchers with a powerful and flexible solution for next-generation genome engineering.

The Alt-R HDR Enhancer Protein is available in RUO format at 500 μg and 5 mg with CGMP grade to follow. The enhancer protein seamlessly integrates into existing workflows, and is compatible with different Cas systems and common delivery methods. IDT’s complete CRISPR workflow—from design to analysis—continues to support gene editing pioneers with optimized Cas9 and Cas12a systems, customizable gRNAs, HDR solutions and analysis tools backed by expert support. These key components have been foundational to enabling some of the world’s greatest genomic breakthroughs, including the world’s first personalized CRISPR therapy.

For Alt-R HDR Enhancer Protein ordering options and to explore additional data, protocols and more, visit www.idtdna.com/HDREnhancerProtein.

About IDT

Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT) has evolved from an oligo manufacturer to a leading genomics provider. We work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Our vision of enabling researchers to rapidly move from the lab to life-changing advances reflects our ongoing commitment to a healthier, brighter future for all.

IDT is proud to be part of Danaher, a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health.

For more information about IDT, visit www.idtdna.com and follow the company on LinkedIn, X, Facebook, YouTube, and Instagram.

Disclaimer: RUO — For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.